Skip to main content

Table 1 Main bisphosphonates used in pediatric age (adapted from Baroncelli G.I. et al.) [90]

From: Growth and puberty in children with juvenile idiopathic arthritis

Name Oral Parenteral Dose Relative potency
Etidronate + + p.o.:5–40 mg/kg per day
iv: 400 mg per day per 2 weeks, every 3 months
1
Clodronate + + p.o.: 200 mg per day /subdivided into 3 doses
iv: (dilute in 200–250 ml NSS, in 2–3 h) 2 mg/kg per day every 3–6 months
10
Pamidronate   + (dilute in 100–250 ml of NSS, in 3–4 h)0.5–1.5 mg/kg per day for 3 days; every 2–6 months) 100
Neridronate   + (dilute in 200–250 ml NSS, in 3 h)1–2 mg/kg per every 3–6 months 100
Zoledronate   + (dilute in 50 ml NSS, in 30–45 min) 0.015–0.05 mg/kg every 3–6 months > 10,000
Aledronate +   1–2 mg/kg/week
<  40 kg: 5 mg/day or 35 mg/week
>  40 kg: 10 mg/day or 70 mg/week
Maximum dose: 70 mg/week
100–1000
Risedronate +   15 mg per week (< 40 kg)
30 mg per week (> 40 kg)
Maximum dose: 30 mg/week
1000–10,000
  1. Abbreviations: iv intravenous, p.o. per os, NSS normal saline solution